Raasgier schreef op 27 maart 2020 21:32:
Wacht, dat is nog maar klein stukje. Naar goed en tegelijk vrij zinloos gebruik plak ik het wel even helemaal:
After a historic 2019, 2020 promises to be a particularly newsflow rich year for Galapagos.
First of all, we and our collaboration partner Gilead expect approval of our first product candidate, filgotinib, in RA in the U.S., Europe, and Japan. We also expect Gilead to report Phase 3 data of filgotinib in ulcerative colitis (UC) in the second quarter of this year. Moreover, Gilead and we plan to start the Phase 3 program with filgotinib in ankylosing spondylitis (AS) later in 2020 – a potential additional indication for our growing filgotinib franchise.
Besides the filgotinib UC read-out, we expect to report data from four Phase 2 clinical trials.
..........
..........
In total, we expect to conduct more clinical trials in 2020 than ever before, further expanding our broad clinical pipeline of novel modes of action candidate medicines in indications with high unmet medical needs.